Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Breast Cancer KOL Insight: Update Bulletin [March 2017]

Product Code:
596200614
Publication Date:
March 2017
Format:
PDF
Price:
£1,140

Breast Cancer KOL Insight Update Bulletin #3 [2016]: March 2017

This edition presents KOL views on recent developments in the breast cancer market. Topics include; positive results from two Phase III studies: Genentech’s APHINITY trial with Perjeta (pertuzumab) in patients with HER2-positive early breast cancer, and AstraZeneca’s OlympiAD trial with Lynparza (olaparib) in patients with HER2-negative metastatic breast cancer harbouring germline BRCA1 or BRCA2 mutations; an analysis of development plans of Cascadian Therapeutics’ tucatinib in patients with HER2-positive breast cancer; and views on the potential of Rexahn Pharmaceuticals’ Supinoxin in patients with triple-negative breast cancer.

Business Questions:

  • How likely is it that Genentech’s Perjeta (pertuzumab) and AstraZeneca’s Lynparza (olaparib) will gain regulatory approval in their respective settings? 
  • What data would be needed for Lynparza to be used in a broader population?
  • What will the future treatment landscape for BRCA 1/2 - associated metastatic breast cancer look like?
  • Could Cascadian Therapeutics’ targeted therapy, tucatinib, be a step change in treatment of HER2-positive metastatic breast cancer?
  • What are the KOLs views on the potential of Rexahn Pharmaceuticals’ Supinoxin in metastatic triple-negative breast cancer patients who have failed prior treatments?



customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved